FDA clears dostarlimab for selected rectal cancer patients after durable response signals
The FDA has granted accelerated approval to Jemperli (dostarlimab-gxly) for adults with previously untreated stage II or stage III locally advanced rectal cancer whose tumors are dMMR or MSI-H. For a small subset of patients, that decision opens a path that can spare the bowel, bladder, sexual function, fertility, and body-image consequences that often follow standard rectal cancer treatment. It also changes the sequence of care itself: rather than moving directly into chemotherapy, radiation, and surgery, some patients may now be monitored after immunotherapy alone.
The drug’s use here is tightly defined. Eligibility depends on two features that are biologically linked: the cancer must be locally advanced, and the tumor must carry mismatch repair deficiency or high microsatellite instability as confirmed by an FDA-authorized test. Published estimates suggest these biomarkers are present in about 3% of locally advanced rectal cancers, so this is not a population-level remedy. It is a precision treatment for a narrow molecular subgroup with an especially high likelihood of immune sensitivity.
A single sentence captures the clinical appeal: some patients may avoid the full triad of chemoradiation, surgery, and permanent ostomy.
Why mismatch repair deficiency makes this tumor vulnerable
Mismatch repair deficiency leaves cancer cells unable to correct DNA copying errors. As mutations accumulate, the tumor generates abnormal proteins that the immune system can more easily recognize. PD-1 blockade works by taking the brakes off immune cells, allowing them to attack the cancer more effectively. In this setting, dostarlimab is not being used as a blunt cytotoxic tool; it is being used to exploit a biologic weakness in the tumor’s own DNA repair machinery.
That mechanism matters in rectal cancer because the standard pathway carries a heavy toxicity burden. Chemotherapy and radiation before surgery can impair bowel, urinary, and sexual function, and may also affect fertility. Surgery adds risks of poor healing, anastomotic leak where the bowel is reconnected, and in some cases a permanent colostomy. When a tumor can be controlled without those interventions, the gain is not simply tumor response. The gain is preservation of function and reduction of life-altering morbidity.
Interim AZUR-1 results drove the accelerated approval
The FDA based its decision on interim results from AZUR-1, a phase 2 study of 154 patients with previously untreated dMMR or MSI-H locally advanced rectal cancer. Participants received up to nine doses of dostarlimab, administered every 3 weeks over 6 months. After a median follow-up of more than 2 years, almost three-fourths of patients had not needed surgery, radiotherapy, or chemotherapy.
That is the central clinical signal behind the approval: many patients remained free of the usual escalation to multimodality treatment after immunotherapy alone. The follow-up is long enough to suggest the effect is not fleeting, but it is still interim data. This is why accelerated approval fits the evidence base. The agency is allowing access before definitive maturation of outcomes, while requiring more data on durability and recurrence.
Longer observation will be essential because rectal cancer is not judged only by immediate radiographic response. Clinicians need to know how long the remission lasts, how often residual disease reappears, and whether delayed salvage treatment remains effective if recurrence occurs. Those questions are especially important when a treatment strategy is designed to defer surgery rather than simply downstage a tumor before resection.
Earlier single-center data point in the same direction
A prior study at Memorial Sloan Kettering Cancer Center enrolled 50 patients with previously untreated dMMR or MSI-H locally advanced rectal cancer and treated them with dostarlimab alone. None of the patients had detectable signs of cancer after treatment, and 93% maintained that cancer-free status for at least 12 months. Among the 27 patients followed for at least 3 years, only one had a recurrence, and it returned in the same area.
Those numbers are small, but they helped establish the biologic plausibility that checkpoint blockade could produce deep responses in this disease. The newer multicenter experience broadened the evidence base enough for federal regulators to act. Together, the two studies suggest a pattern that is difficult to ignore: in biomarker-selected rectal cancer, immunotherapy can sometimes produce durable control without immediate local therapy.
Safety remains a real tradeoff
Immune-related toxicity is the other side of the ledger.
Because Jemperli activates the immune system, it can also cause immune cells to attack healthy tissue. Those reactions can be severe or fatal. In the rectal cancer population described here, the most common adverse effects reported in at least 15% of patients were fatigue, rash, diarrhea, and itching. Diarrhea deserves particular clinical attention because it may overlap symptomatically with the disease process or with prior pelvic treatment effects, and immune-mediated colitis can become urgent if it progresses.
The approval therefore does not eliminate clinical risk; it shifts the risk profile. Instead of surgical and radiation morbidity, clinicians must now watch for immune-mediated adverse events and manage them promptly. Patient selection, biomarker confirmation, and close follow-up remain central.
Accelerated approval brings access, but also unfinished evidence
The agency granted Priority Review and Breakthrough Therapy designation to this use of dostarlimab, and the action marks the 11th approval reviewed under the Commissioner’s National Priority Voucher pilot program. Those regulatory pathways signal urgency around treatments that address major public health needs, but they do not remove the requirement for verification. Because the approval rests on interim trial data, the sponsor must continue following patients to show that these responses translate into lasting clinical benefit.
For oncologists, the practical question is no longer whether the tumor can sometimes disappear with PD-1 blockade alone. The question is how reliably that response can be sustained, which patients are most likely to benefit, and how best to monitor for recurrence if surgery and radiation are deferred. The answer will come from longer follow-up, not from enthusiasm alone. Until then, this approval represents a tightly restricted option for a biomarker-defined subgroup, with durable disease control still needing confirmation over time.